Suppression of testosterone production using abiraterone acetate (AA) with or without androgen deprivation therapy (ADT) in metastatic castration resistant prostate cancer (mCRPC).

被引：3
|
作者：
Jha, Gautam Gopalji
Jeff, Engle
机构：
[1] Univ Minnesota, Minneapolis, MN USA
[2] Fairview Pharm Serv, Minneapolis, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5049
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Predictors of outcome to post-docetaxel abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (p)
    Ochoa de Olza, M.
    Font, A.
    Sala, N.
    Beltran, M.
    Barretina, P.
    Etxaniz, O.
    Indacoechea, A.
    Hernandez, A.
    Navarro, V.
    Germa, J. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S701 - S701
  • [23] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [24] Results of a phase II trial of abiraterone acetate (AA) combined with dutasteride (DUT) for men with metastatic castration resistant prostate cancer (mCRPC).
    McKay, Rana R.
    Werner, Lillian
    Zukotynski, Katherine A.
    Domachevsky, Liran
    Elfiky, Aymen
    Pomerantz, Mark M.
    Bubley, Glenn J.
    Montgomery, Robert B.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [25] Cabazitaxel in metastatic castrate resistant prostate cancer (mCRPC) in the era of enzalutamide (ENZA) and abiraterone acetate (AA).
    Body, Amy
    Pranavan, Gane
    Malik, Laeeq
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] Castration Resistant Prostate Cancer: Androgen blockade by abiraterone acetate is convinced
    Kriegeskorte, Volker
    AKTUELLE UROLOGIE, 2011, 42 (05) : 275 - 275
  • [27] Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer
    Bilgin, Burak
    Sendur, Mehmet A. N.
    Hizal, Mutlu
    Akinci, Muhammed Bulent
    Dede, Didem Sener
    Yalcin, Bulent
    FUTURE ONCOLOGY, 2017, 13 (22) : 1911 - 1913
  • [28] Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC)
    Gill, David Michael
    Agarwal, Neeraj
    Hahn, Andrew W.
    Johnson, Eric
    Poole, Austin
    Carroll, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [29] Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
    Martini, Alberto
    Fallara, Giuseppe
    Ploussard, Guillaume
    Malavaud, Bernard
    LANCET ONCOLOGY, 2023, 24 (10): : 1056 - 1057
  • [30] Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC).
    von Klot, Christoph A. J.
    Boeker, Alena
    Herrmann, Thomas R. W.
    Kramer, Mario W.
    Kuczyk, Markus A.
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345